The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
News|Articles|February 12, 2025
Oncology Experts Preview Top Abstracts From 2025 ASCO GU
Author(s)Kristi Rosa
Fact checked by: Chris Ryan
Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.
Advertisement
Advertisement
Ahead of this year’s Genitourinary Cancers Symposium, OncLive® asked leading oncologists in the space to share what presentations they are most excited to learn more about during the meeting and why.
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Phase 2 data show adjuvant penpulimab significantly improves disease-free survival vs surveillance in very high-risk clear cell renal cell carcinoma.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Advertisement
Advertisement